




## CLINICAL STUDY RESULTS



### More time in range\*

Average additional time in range per day for study participants who used Control-IQ technology.<sup>1</sup>



### Said it's easy to use

Percent of study participants who used Control-IQ technology and said it was easy to use.<sup>2</sup>

## It's easy to get started

To begin the process, visit:  
[tandemdiabetes.com/getstarted](http://tandemdiabetes.com/getstarted)

\* As measured by CGM. † If glucose values are predicated to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value. An Automatic Correction Bolus will not occur within 60 minutes of a bolus that has been delivered or cancelled. ‡ If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. § Additional feature updates are not currently available for the t:slim X2 insulin pump with Control-IQ technology and are subject to regulatory approvals. Future updates for some or all of Tandem's products may not be developed and may not be offered everywhere. Software updates are only available to customers who are in warranty at the time they update their pump, and may require a prescription and additional training. Charges may apply. Tandem may discontinue select software and features over time at its discretion.

**References:** 1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. *N Eng J Med*. 2019;381(18):1701-1717. 2. Brown, S. Clinical Acceptance of the Artificial Pancreas: Glycemia Outcomes from a 6-month Multicenter RCT. 2019 ADA 79th Scientific Sessions, San Francisco, CA. 3. 38% smaller than MiniMed 630G and 670G and at least 28% smaller than MiniMed 530G, Animas Vibe, and Omnipod System. Data on file, Tandem Diabetes Care.

**Important Safety Information:** RX ONLY. The t:slim X2 pump and Control-IQ technology are intended for single patient use. The t:slim X2 pump and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin. **t:slim X2 insulin pump:** The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The t:slim X2 pump is indicated for use in individuals six years of age and greater. **Control-IQ technology:** Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater.

**WARNING:** Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. Visit [tandemdiabetes.com/safetyinfo](http://tandemdiabetes.com/safetyinfo) for additional important safety information.

© 2020 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Control-IQ, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries. All other third-party marks are the property of their respective owners. ML1005029\_B



**TANDEM®**  
DIABETES CARE

(877) 801-6901  
[tandemdiabetes.com](http://tandemdiabetes.com)

t:slim X2 Insulin Pump  
WITH **Control-IQ** TECHNOLOGY

See How Easy  
**Control**  
Can Be



Stacy  
diagnosed 2006

# Introducing Control-IQ Technology

Trying to keep your blood sugar in range can be stressful and time consuming. Our new Control-IQ™ advanced hybrid closed-loop technology makes it easier by predicting and helping prevent both highs and lows.









*Mide*  
diagnosed 2012



## How Does Control-IQ Work?

Control-IQ technology is designed to help increase time in range (70–180 mg/dL)\* by using Dexcom G6 continuous glucose monitoring (CGM) values to predict blood glucose levels 30 minutes ahead and adjust insulin delivery accordingly, including delivery of automatic correction boluses† (up to one per hour). There are also optional settings for Sleep and Exercise that will change the range of treatment values to better match the different physiologic needs during these activities.

180	  <b>Delivers</b>	Delivers an automatic correction bolus if sensor glucose is predicted to be above 180 mg/dL
160	 <b>B Increases</b>	Increases basal insulin delivery if sensor glucose is predicted to be above 160 mg/dL
112.5	 <b>B Maintains</b>	Maintains active Personal Profile settings
70	 <b>B Decreases</b>	Decreases basal insulin delivery if sensor glucose is predicted to be below 112.5 mg/dL
mg/dL	 <b>0 Stops</b>	Stops basal insulin delivery if sensor glucose is predicted to be below 70 mg/dL



Zero  
Fingersticks‡



Remote Software  
Updates§



Simple User  
Interface



Smallest  
Available Pump³



Responsible Use  
of Control-IQ  
Technology

Control-IQ technology does not prevent all highs and lows. You must still bolus for meals and actively manage your diabetes. Please visit [tandemdiabetes.com/tslimX2-use](http://tandemdiabetes.com/tslimX2-use) for more information.

‡ If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.